Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Past and present commissioners of the U.S. Food and Drug Administration, both with ties to Duke University, are among the speakers headlining the Council for Entrepreneurial Development’s 26th annual Life Science Conference next month in Raleigh. Confirmed speakers at the conference include Adele Oliva, Ibraheem Badejo, and James C. Greenwood.
1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies today announced the recent expansion of its team with the addition of Edward Chan.
Onkos Surgical has announced today it has received clearance from the U.S. Food and Drug Administration to market the ELEOS™ Limb Salvage System to treat patients with significant bone loss due to cancer, trauma, or previous surgical procedures.
The Philadelphia Business Journal honored Adele Oliva as part of the Power 76, a guide to the region’s most influential people. They narrowed in on those wielding the most influence, either through their position, their connections or their money. These are the people with the most impact in shaping the future of Greater Philadelphia.
Encore Dermatology, Inc., a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of HylatopicPlus® Lotion in a convenient 14 oz. bottle with pump dispenser.
1315 Capital today announced the final closing of its $200 million inaugural fund. The fund is led by seasoned healthcare investors and 1315 Capital’s Co-Founders, Adele Oliva and Michael Koby, and includes a select group of high quality investors, including endowments, foundations, state and corporate pension funds, and family offices.
Onkos Surgical and Vivex Biomedical, Inc. have come together to provide a portfolio of tissue products to support the needs of musculoskeletal oncologists and their patients. This commitment strengthens Onkos Surgical’s ability to enhance outcomes, decrease complications and improve recovery following musculoskeletal tumor and limb salvage surgery.
Nutrition 21, LLC, a leading developer and marketer of efficacious, patented nutritional products whose health benefits are substantiated with clinical research, announced today that Sara O’Brien has joined as General Counsel of JDS Therapeutics, and its wholly owned subsidiary Nutrition 21.
Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of new clinical study results supporting the bioavailability of Nitrosigine® bonded arginine silicate (ASI), titled, “A Pharmacokinetic Evaluation of the Duration of Effect of Inositol-Stabilized Arginine Silicate and Arginine Hydrochloride in Healthy Adult Males.” The study was presented on April 3rd, 2016 to scientists …